Skip to main content
SpringerLink
Log in

Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease

A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study

  • Clinical Use
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background: Influenza in patients with asthma can cause acute exacerbation and in patients with chronic obstructive pulmonary disease (COPD) it can lead to respiratory distress. Zanamivir is an effective treatment for both influenza A and B. However, controlled studies with zanamivir specifically in asthma or COPD patients with influenza illness are limited.

Objective: To investigate the clinical efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or COPD.

Design and Setting: This randomised, double-blind, placebo-controlled, multi-centre study was conducted at 159 sites in 15 countries.

Patients and Participants: 525 patients with asthma or COPD aged ≥12 years and with influenza-like illness were enrolled; 313 (60%) of these had laboratory-confirmed influenza virus infection and were included in the primary efficacy analysis.

Methods: Patients were randomised to inhaled zanamivir 10mg or matching placebo via Diskhaler™ twice daily for 5 days. Patients recorded symptoms and pulmonary function twice daily in diary cards. The primary end-point in both patient groups was time to alleviation of symptoms of influenza.

Results: Zanamivir significantly reduced the median time to alleviation of influenza symptoms compared with placebo (5.5 days vs 7.0 days; difference 1.5 days; 95% confidence interval 0.50 to 3.25 days; p = 0.009). Zanamivir significantly reduced the mean overall influenza assessment score compared with placebo (p = 0.004) over days 1 to 5. Patients recorded fewer nights of sleep disturbance with zanamivir compared with placebo (median 2 nights vs 3 nights; p = 0.042) during treatment. Zanamivir reduced the incidence of complications (requiring antibiotics and a change in respiratory medication) compared with placebo by 58% (p = 0.064). Zanamivir did not adversely affect pulmonary function, as determined by measurements of forced expiratory volume in 1 second and peak expiratory flow rate, compared with placebo. Zanamivir was well tolerated, with a safety profile similar to placebo. Compliance with treatment was high, with 495 (94%) patients successfully completing at least 4 days of treatment (8 doses). Furthermore, 90% of patients felt that the Diskhaler™ was easy or very easy to use.

Conclusion: Zanamivir is an effective treatment for influenza in patients with asthma or COPD, and has a safety profile similar to that of placebo. Importantly, zanamivir does not adversely affect pulmonary function in this high-risk population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Table III

Similar content being viewed by others

References

  1. Watson J. Surveillance of influenza. In: ei]holson G, Webster RG, Hay AJ, editors. Textbook of influenza. London: Black-well Science, 1998: 207–16

    Google Scholar 

  2. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Oxford. Textbook of influenza. Oxford: Black-well Science, 1998: 219–64

    Google Scholar 

  3. Cate TR. Clinical manifestations and consequences of influenza. Am JMed 1987; 82: 15–9

    CAS  Google Scholar 

  4. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978–1981. Am Rev Respir Dis 1987; 136:550–5

    Article  PubMed  CAS  Google Scholar 

  5. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982; 142: 85–9

    Article  PubMed  CAS  Google Scholar 

  6. Lui KJ, Kendal AR Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Pub Health 1987; 77(6): 712–6

    Article  CAS  Google Scholar 

  7. Centre for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48 (RR-4): 1–28

    Google Scholar 

  8. Centre for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2000; 49 (RR-3); 1–38

    Google Scholar 

  9. Szilagyi PG, Rodewald LE, Savageau J, et al. Improving influenza vaccination rates in children with asthma: a test of a computerized reminder system and an analysis of factors predicting vaccination compliance. Pediatrics 1992; 90: 871–5

    PubMed  CAS  Google Scholar 

  10. Wiselka MJ, Kent J, Nicholson KG, et al. Influenza and asthma [letter]. Lancet 1992; 339: 367–8

    Article  PubMed  CAS  Google Scholar 

  11. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696–702

    Article  PubMed  CAS  Google Scholar 

  12. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Curr Opin Infect Dis 1994; 7: 674–7

    Article  Google Scholar 

  13. Belshe RB, Burk B, Newman F, et al. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430–5

    Article  PubMed  CAS  Google Scholar 

  14. Hayden FG, Gwaltney JM, Jr, Van de Castle RL, et al. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother 1981; 19: 226–33

    Article  PubMed  CAS  Google Scholar 

  15. Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother 1983; 23: 458–64

    Article  PubMed  CAS  Google Scholar 

  16. Aoki FY. Amantadine and rimantadine. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science, 1998: 457–76

    Google Scholar 

  17. Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473–9

    Article  PubMed  CAS  Google Scholar 

  18. Barnett, J, Cadman, A, Gor, D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000; 44: 78–79

    Article  PubMed  CAS  Google Scholar 

  19. Osterhaus A, Tisdale M, Elliott M. A double-blind, randomised trial of zanamivir in the treatment of acute influenza: clinical and virological efficacy results [abstract]. 38th International Conference of Antimicrobial Agents and Chemotherapy: 1998 Sep 24–28; San Diego, 11

  20. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877–81

    Article  Google Scholar 

  21. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337: 874–80

    Article  PubMed  CAS  Google Scholar 

  22. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomised, double-blind, placebo-controlled European study. J Infect 2000; 40: 42–8

    Article  PubMed  CAS  Google Scholar 

  23. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254–61

    Article  PubMed  CAS  Google Scholar 

  24. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med. In press

  25. Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 1997; 112: 591–6

    Article  PubMed  CAS  Google Scholar 

  26. Kondo S, Abe K. The effects of influenza virus infection on FEV1 in asthmatic children. The time-course study. Chest 1991; 100: 1235–8

    Article  PubMed  CAS  Google Scholar 

  27. Roldaan AC, Masural N. Viral respiratory infections in asthmatic children staying in a mountain resort. Eur J Respir Dis 1982; 63: 140–50

    PubMed  CAS  Google Scholar 

  28. Sears MR. Descriptive epidemiology of asthma. Lancet 1997; 350(Suppl 2): 1–4

    Article  Google Scholar 

  29. Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342: 661–2

    Article  PubMed  CAS  Google Scholar 

  30. Relenza™: European summary of product characteristic. Greenford: Glaxo Wellcome, 2000

  31. Cass LMR, Gunawardena KA, Macmahon MM, et al. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med 2000; 94: 166–73

    Article  PubMed  CAS  Google Scholar 

  32. Ware JE, Nelson EC, Sherbourne CD, et al. Preliminary tests of 6-item general health survey: a patient application. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham, NC: Duke University Press, 1992

  33. Ware JE, Kosinski M, Dewey JE. How to score and interpret single-item health status measures: a manual for users of the SF6 and SF8 health surveys. Lincoln, RI: Quality Metric Incorporated, 1999

    Google Scholar 

  34. Noether GE. Sample size determination for some common non-parametric tests. J Am Stat Assoc 1987; 82: 645–7

    Article  Google Scholar 

  35. Lehmann E. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day Inc, 1975

    Google Scholar 

  36. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993: 168–77

    Google Scholar 

  37. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307: 982–6

    Article  PubMed  CAS  Google Scholar 

  38. Fagon JY, Chastre J. Severe exacerbations of COPD patients: the role of pulmonary infections. Semin Respir Infect 1996; 11: 109–18

    PubMed  CAS  Google Scholar 

  39. Jokic R, Fitzpatrick ME. Obstructive lung disease and sleep. Med Clin North Am 1996; 80: 821–50

    Article  PubMed  CAS  Google Scholar 

  40. Lewis DA. Sleep in patients with respiratory disease. Respir Care Clin North Am 1999; 5: 447–60

    CAS  Google Scholar 

  41. D’Ambrosio CM, Mohsenin V. Sleep in asthma. Clin Chest Med 1998 Mar; 19: 127–37

    Article  PubMed  Google Scholar 

  42. Park CL, Frank A. Does influenza vaccination exacerbate asthma? Drug Safety 1998; 19: 83–8

    Article  PubMed  CAS  Google Scholar 

  43. Nicholson KG, Nguyen-Van-Tam JS, Ahmed AH, et al. Randomised placebo-controlled crossover trial on effect of inactivated influenza vaccine on pulmonary function in asthma. Lancet 1998; 351: 326–31

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Funding for this study (protocol number NAI30008) was provided by Glaxo Wellcome Research and Development, Greenford, UK. We thank the following for their contribution to this study: each of the 159 investigators who participated in this study, and Richard Glover for assistance with preparation of the manuscript.

Author information

Authors and Affiliations

  1. Midwest Allergy and Asthma Clinic, Omaha, Nebraska, USA

    Kevin R. Murphy

  2. Havblik Medical Center, Arendal, Norway

    Arne Eivindson

  3. Infektionskliniken, Akademiska Sjukhuset, Uppsala, Sweden

    Karlis Pauksens

  4. Twelve Corners Internal Medicine Group, Rochester, New York, USA

    William J. Stein

  5. Hotel Dieu de St-Jerome, St-Jerome, Quebec, Canada

    Guy Tellier

  6. The Investigator Clinic, Port Lincoln, South Australia, Australia

    Richard Watts

  7. Service de Pneumologie et Allergologie, Hôpital Rangueil, Toulouse, France

    Paul Léophonte

  8. Glaxo Wellcome Research and Development, Greenford, Middlesex, England

    Stephen J. Sharp & Elke Loeschel

Authors
  1. Kevin R. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arne Eivindson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karlis Pauksens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William J. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guy Tellier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul Léophonte
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Stephen J. Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Elke Loeschel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murphy, K.R., Eivindson, A., Pauksens, K. et al. Efficacy and Safety of Inhaled Zanamivir for the Treatment of Influenza in Patients with Asthma or Chronic Obstructive Pulmonary Disease. Clin. Drug Investig. 20, 337–349 (2000). https://doi.org/10.2165/00044011-200020050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200020050-00005

Keywords

Search

Navigation